Subgroup Interactions in the Heart and Estrogen/Progestin Replacement Study Lessons Learned
作者： Curt D. Furberg , Eric Vittinghoff , Michael Davidson , David M. Herrington , Joel A. Simon
关键词:
摘要: Background— The Heart and Estrogen/Progestin Replacement Study (HERS) showed no overall benefit of postmenopausal hormone treatment in women with coronary heart disease (CHD). We analyzed the HERS data to determine whether there were specific subgroups who responded differently treatment, either during first year or study. Methods Results— In search for significant interactions, we a total 86 defined by baseline characteristics. These included demographics lifestyle factors, laboratory physical examination variables, medical history symptoms self-report, medication use, prior CHD chart review. examined within-subgroup effects variables that significantly interacted assignment. Under null hypothesis, 4 (5%) interactions would be expected nominally (P<0.05) chance alone at each time point. Six interaction values P<0.05 at...
sci-hub.se 参考文章(16)
Deborah Grady, William Applegate, Trudy Bush, Curt Furberg, Betty Riggs, Stephen B. Hulley, Heart and Estrogen/progestin Replacement Study (HERS) Controlled Clinical Trials. ,vol. 19, pp. 314- 335 ,(1998) , 10.1016/S0197-2456(98)00010-5
Michael G. Shlipak, Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. JAMA. ,vol. 283, pp. 1845- 1852 ,(2000) , 10.1001/JAMA.283.14.1845
S. Aebi, T. W. Schnider, G. Los, D. D. Heath, D. Darrah, S. Kirmani, E. F. McClay, H. D'Agostino, S. C. Plaxe, D. Fink, M. M. De las Alas, S. B. Howell, R. D. Christen, A phase II/pharmacokinetic trial of high-dose progesterone in combination with paclitaxel Cancer Chemotherapy and Pharmacology. ,vol. 44, pp. 259- 265 ,(1999) , 10.1007/S002800050976
Bruce M Psaty, Nicholas L Smith, Rozenn N Lemaitre, Hans L Vos, Susan R Heckbert, Andrea Z LaCroix, Frits R Rosendaal, None, Hormone Replacement Therapy, Prothrombotic Mutations, and the Risk of Incident Nonfatal Myocardial Infarction in Postmenopausal Women JAMA. ,vol. 285, pp. 906- 913 ,(2001) , 10.1001/JAMA.285.7.906
Lawrence M. Friedman, Fundamentals of Clinical Trials ,(1982)
K L Lee, J F McNeer, C F Starmer, P J Harris, R A Rosati, Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. Circulation. ,vol. 61, pp. 508- 515 ,(1980) , 10.1161/01.CIR.61.3.508
W. S. Browner, S. B. Hulley, Effect of risk status on treatment criteria. Implications of hypertension trials. Hypertension. ,vol. 13, ,(1989) , 10.1161/01.HYP.13.5_SUPPL.I51
Stephen Hulley, Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women JAMA. ,vol. 280, pp. 605- 613 ,(1998) , 10.1001/JAMA.280.7.605
Eats Haverkate, Simon G Thompson, Stephen DM Pyke, J Ruth Gallimore, Mark B Pepys Group, Production of C-reactive protein and risk of coronary events in stable and unstable angina The Lancet. ,vol. 349, pp. 462- 466 ,(1997) , 10.1016/S0140-6736(96)07591-5
Lori Mosca, Peter Collins, David M Herrington, Michael E Mendelsohn, Richard C Pasternak, Rose Marie Robertson, Karin Schenck-Gustafsson, Sidney C Smith, Jr, Kathryn A Taubert, Nanette K Wenger, Hormone Replacement Therapy and Cardiovascular Disease A Statement for Healthcare Professionals From the American Heart Association Circulation. ,vol. 104, pp. 499- 503 ,(2001) , 10.1161/HC2901.092200